Repligen

Yahoo Finance • last month

Repligen Corporation to Present at Upcoming September Conferences

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.... Full story

Yahoo Finance • 2 months ago

Repligen partners with Novasign to enhance bioprocessing systems

WALTHAM, Mass. - Repligen Corporation (NASDAQ:RGEN), a bioprocessing company with a market capitalization of $6.9 billion and annual revenue of $650 million, has formed a strategic partnership with Austria-based Novasign to integrate machi... Full story

Yahoo Finance • 2 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership... Full story

Yahoo Finance • 2 months ago

Repligen Corp (NASDAQ:RGEN) Q2 2025 Earnings: Revenue Beat Offsets EPS Miss as Stock Rises in Pre-Market

REPLIGEN CORP (NASDAQ:RGEN [https://www.chartmill.com/stock/quote/RGEN]) Q2 2025 EARNINGS: REVENUE BEATS ESTIMATES, EPS MISSES AMID MARKET REACTION Repligen Corp reported its second-quarter 2025 financial results, delivering mixed perform... Full story

Yahoo Finance • 2 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than 20% year-over-yearIncreasing revenue guidance to range of $715 to $735 million, which represents... Full story

Yahoo Finance • 2 months ago

Repligen Q2 2025 Earnings Preview

* Repligen (NASDAQ:RGEN [https://seekingalpha.com/symbol/RGEN]) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. * The consensus EPS Estimate is $0.39 [https://seekingalpha.com/symbol/RGEN/earning... Full story

Yahoo Finance • 2 months ago

Repligen's 39% decline validates InvestingPro's January 2024 bearish call

When InvestingPro’s Fair Value models identified Repligen Corporation (NASDAQ:RGEN) as significantly overvalued in January 2024, the bioprocessing company was trading at $193.40. Today, after an 18-month period that saw the stock decline b... Full story

Yahoo Finance • 2 months ago

Repligen to Report Second Quarter 2025 Financial Results

WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release... Full story

Yahoo Finance • 3 months ago

Repligen's SWOT analysis: bioprocessing leader's stock faces growth challenges

Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing company valued at $7 billion, has been making waves in the biopharmaceutical industry with its innovative products and strategic acquisitions. As the company navigates through a p... Full story

Yahoo Finance • 3 months ago

Barclays initiates Repligen stock with overweight rating on bioprocessing strength

Investing.com - Barclays initiated coverage on Repligen (NASDAQ:RGEN) with an overweight rating and a $150.00 price target on Monday. The research firm cited Repligen’s positioning as a bioprocessing pure-play company, noting the sector’s... Full story

Yahoo Finance • 3 months ago

908 Devices appoints co-founder Christopher Brown to board of directors

BOSTON - 908 Devices Inc. (NASDAQ:MASS), a company specializing in handheld devices for chemical analysis, announced Monday the appointment of Christopher D. Brown, PhD, to its Board of Directors, effective immediately. Brown, a co-founde... Full story

Yahoo Finance • 4 months ago

Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report

WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Rep... Full story

Yahoo Finance • 4 months ago

Repligen Corporation to Present at William Blair Growth Conference

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual G... Full story

Yahoo Finance • 5 months ago

Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conf... Full story

Yahoo Finance • 5 months ago

Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Revenue: $169 million for Q1 2025, a 10% increase year-over-year. Organic Revenue Growth: 11% overall, 14% organic non-COVID growth. Adjusted Gross Margin: 53.7%, up nearly 450 basis points from last year. Adjusted Income from Operations:... Full story

Yahoo Finance • 5 months ago

Repligen (RGEN) Q1 Earnings: What To Expect

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for. Repligen met analysts’ revenue expectations last quarter, reporting revenues of $167.5 milli... Full story

Yahoo Finance • 5 months ago

Repligen to Report First Quarter 2025 Financial Results

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press releas... Full story

Yahoo Finance • 6 months ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team... Full story

Yahoo Finance • 7 months ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built ha... Full story

Yahoo Finance • 7 months ago

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth quarter revenue of $168 million and full year revenue of $634 million Fourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guida... Full story